Belgian Entertainment Stock News

If you are wondering whether argenx is still worth buying after its big run over the past few years, you are not alone. This is exactly the question we are going to unpack. The stock has pulled back recently, with the share price down 3.8% over the last week and 7.7% over the past month, but it is still up 19.2% year to date and 190.3% over 5 years. Behind these moves, investors have been reacting to a steady stream of clinical and regulatory updates around argenx's autoimmune pipeline, as...

Azelis Group (EBR:AZE) has had a rough three months with its share price down 22%. However, stock prices are usually...

Key Insights Cenergy Holdings' significant public companies ownership suggests that the key decisions are influenced by...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Colruyt Group (ENXTBR:COLR) has opened H1 2026 with total revenue of €5.5 billion and basic EPS of €1.17, setting the stage for investors to weigh modest top-line progress against earnings power. The group has seen revenue move from €5.39 billion in H2 2024 to €5.43 billion in H1 2025 and now €5.54 billion in H2 2025, while basic EPS shifted from €1.29 to €1.54 and then €1.17 over the same periods. With trailing net profit margin at 2.7% and earnings forecast to grow faster than revenue, the...

As Europe navigates a mixed economic landscape, with indices like the STOXX Europe 600 showing slight declines and varied performances across major markets, investors are closely watching central bank policies and economic data for cues. In such an environment, dividend stocks yielding over 3.1% can offer potential stability and income, making them attractive options for those looking to balance risk with steady returns amidst fluctuating market conditions.

Wondering if Solvay at around €26.88 is a value opportunity hiding in plain sight, or just a stock stuck in neutral? Let us walk through what the numbers are really saying about its current price tag. Over the last week Solvay has inched up about 2.0%, but it is still down roughly 13.2% year to date and 9.0% over the past year, despite being up close to 60% over three years and 66.6% over five. These moves come as Solvay continues its multi year portfolio reshaping and strategic focus on...

Warehouses De Pauw SA has announced an increased annual dividend of €0.8610 per share, already paid on May 5, 2026, following an ex-date of April 30 and a record date of May 4. This higher cash payout highlights management’s willingness to return more capital to shareholders, potentially reinforcing confidence in the company’s cash generation and balance-sheet strength. We’ll now examine how this higher annual dividend commitment feeds into Warehouses De Pauw’s existing investment narrative...

NV Bekaert SA's ( EBR:BEKB ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now...

Those holding Ekopak NV ( EBR:EKOP ) shares would be relieved that the share price has rebounded 27% in the last thirty...

On 15 December 2025, argenx SE said it would discontinue its Phase 3 UplighTED trials of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease after an Independent Data Monitoring Committee found the study was unlikely to meet its efficacy goals, despite a favorable safety profile and no new safety signals. The company now plans a full analysis of the interim data to understand why the drug underperformed on proptosis response and other endpoints, and to extract...

Earlier in December 2025, UCB reported positive Phase 3 data at the American Epilepsy Society meeting showing adjunctive fenfluramine significantly reduced seizure frequency in children and adults with CDKL5 deficiency disorder, meeting its primary and key secondary endpoints over 14 weeks. This outcome strengthens fenfluramine’s clinical profile in a rare, severe epilepsy where no approved treatments currently exist, potentially broadening UCB’s neurology footprint if regulators eventually...

The Crescent NV ( EBR:OPTI ) share price has softened a substantial 29% over the previous 30 days, handing back much of...

SCR-Sibelco (ENXTBR:094426466) has quietly outperformed over the past year, even as returns were mixed in the past 3 years and 5 years. This makes the current share price worth a closer look. See our latest analysis for SCR-Sibelco. With the share price now at $4,700 and a modest 1 month share price return of 1.73 percent, the real story is the 1 year total shareholder return of 9.3 percent, which suggests momentum is quietly rebuilding after a tougher multi year patch. If SCR-Sibelco’s...

Ontex Group has announced that Europe Division President Laurent Nielly will succeed Gustavo Calvo Paz as CEO after the May 5, 2026 shareholders’ meeting, while also cutting its 2025 revenue outlook and warning of a high single digit like-for-like revenue drop in the fourth quarter versus last year. At the same time, Ontex is tripling baby pants production capacity in North America to support retailer-brand growth in a segment where U.S. consumers are increasingly opting for affordable,...

As European markets navigate mixed performances, with Germany's DAX showing gains while the UK and France face slight declines, investors are closely monitoring economic indicators and central bank policies for potential opportunities. In this dynamic environment, identifying promising stocks often involves looking at companies that can thrive amidst economic resilience and shifting interest rate expectations.

With its stock down 11% over the past three months, it is easy to disregard Melexis (EBR:MELE). However, the company's...

argenx (ENXTBR:ARGX) heads into the Antibody Engineering and Therapeutics conference in San Diego, with investors watching closely for fresh signals on its antibody pipeline and what that might mean for the stock. See our latest analysis for argenx. The conference buzz comes after a strong run for argenx, with the share price now at $753.2 and a roughly 18% 3 month share price return contributing to a 106% three year total shareholder return. This suggests momentum is still very much on its...

Key Insights The projected fair value for Campine is €183 based on 2 Stage Free Cash Flow to Equity Campine's €180...

Key Insights The projected fair value for Lotus Bakeries is €6,590 based on 2 Stage Free Cash Flow to Equity Lotus...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Wondering if ageas is still good value after a strong run, or if most of the upside is already baked in? You are not alone, and this article will help you size that up calmly. The stock is up 21.6% year to date and 27.3% over the last 12 months, even after a modest 1.0% pullback over the past month. This suggests the market has been reassessing its prospects over time. Recent news flow around European insurers has focused on tighter capital rules, shifts in interest rate expectations and how...

DEME Group has recently secured three contracts to install monopile foundations, inter-array cables and an export cable for the BC-Wind offshore wind farm in Poland, reinforcing its role in the country’s renewable energy rollout. These wins further deepen DEME’s exposure to offshore wind infrastructure, expanding its project pipeline in a market focused on accelerating its energy transition. We’ll now examine how securing BC-Wind’s foundation and cable installation work could influence...